SynapDx Corp. said Tuesday that it has received $6 million in financing to support further development of a blood-based diagnostic test for the early detection of autism spectrum disorders, or ASD.
According to a press release from Southborough-based SynapDx, its test is designed to identify children with ASD by age 36 months. While one US child in 88 is are diagnosed with autism in the United States, only two in 10 are identified by age 36 months, the company said. As a result, the test has the potential to hasten the diagnostic process and help children at risk for ASDs secure access to the right evaluations and treatment as early as possible.
SynapDx said it received the financing from North Bridge Venture Partners and General Catalyst Partners.
“SynapDx has proven that it has the right combination of scientific, clinical, and entrepreneurial expertise to develop tests that will offer parents and pediatricians a better, faster way to identify these disorders,” Bill Geary of North Bridge Venture Partners said in a statement. “The company’s next phase of clinical development will be critical to thousands of children and their families.”Chris Reidy can be reached at firstname.lastname@example.org.